XTX Topco Ltd Makes New Investment in Apogee Therapeutics, Inc. (NASDAQ:APGE)

XTX Topco Ltd bought a new position in Apogee Therapeutics, Inc. (NASDAQ:APGE) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 17,930 shares of the company’s stock, valued at approximately $706,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Darwin Global Management Ltd. bought a new stake in Apogee Therapeutics in the 1st quarter worth about $55,300,000. Vanguard Group Inc. grew its holdings in shares of Apogee Therapeutics by 60.7% in the first quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company’s stock valued at $124,173,000 after acquiring an additional 705,795 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Apogee Therapeutics by 51.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,170,327 shares of the company’s stock valued at $77,770,000 after acquiring an additional 399,646 shares during the last quarter. Farallon Capital Management LLC bought a new stake in Apogee Therapeutics during the first quarter worth $20,267,000. Finally, Jennison Associates LLC boosted its position in Apogee Therapeutics by 192.0% in the first quarter. Jennison Associates LLC now owns 302,892 shares of the company’s stock worth $20,127,000 after purchasing an additional 199,148 shares during the last quarter. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Insider Transactions at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 5,995 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total value of $225,412.00. Following the transaction, the insider now owns 294,793 shares in the company, valued at $11,084,216.80. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Carl Dambkowski sold 5,995 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total value of $225,412.00. Following the sale, the insider now directly owns 294,793 shares in the company, valued at approximately $11,084,216.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jane Henderson sold 6,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $48.26, for a total transaction of $289,560.00. Following the sale, the chief financial officer now directly owns 200,871 shares in the company, valued at $9,694,034.46. The disclosure for this sale can be found here. Insiders sold a total of 120,995 shares of company stock worth $5,218,774 in the last quarter. Insiders own 36.10% of the company’s stock.

Apogee Therapeutics Price Performance

Shares of NASDAQ:APGE opened at $58.43 on Monday. Apogee Therapeutics, Inc. has a 1 year low of $14.19 and a 1 year high of $72.29. The company has a market capitalization of $3.42 billion, a PE ratio of -11.13 and a beta of 2.74. The business has a fifty day moving average price of $47.99 and a two-hundred day moving average price of $49.89.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.60). Sell-side analysts anticipate that Apogee Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.